Charity registration number 1137689 {England and Wales) Charity registration number SC049777 (Scotlandl Company rgglstratlon numbgr 07272699 {England and Wal9$1 PANCREATIC CANCER ACTION ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 PANCREATIC CANCER ACTION LEGAL AND ADMINISTRATIVE INFORMATION Trusts9S N Menezes R Legg C Carter E Cowan N Longworth L Nylander G Codacci Pisanelli (Appointed 18 March 20241 D Slaler (Appointed 18 March 20241 G Lesca (Appointed 18 March 20241 Se¢rotsry G Brown (Resigned 12 January 20231 Charlty numb&r (England and Wales} 1137689 Charlty number (Scotlandl SC049777 Company number 07272699 Registered office BASE Bordon Innovation Centre Broxhead House 60 Barbados Road Bordon GU35 OFX Audltor Alliolls LLP 3 London Square Cross Lanes Guildford GU1 1UJ PANCREATIC CANCER ACTION CONTENTS Pagg CEO'S report Trustees. report Independent auditorfs report 9-11 Stslemenl of financial activities 12 Balance sheet Stslemenl of cash flows 17 Notes lo the financial ststemenls 14-26 PANCREATIC CANCER ACTION CEO'S REPORT FOR THE YEAR ENDED 31 DECEMBER 2023 The year 2023 was one of change and growth for Pancreatic Can￿r Action while Continuing to champion the voice of patients and families, support individuals in a lime of crisis and campaign ID improve earfy diagnosis and save lives. During the year we welcomed a new Chief Executive for the first lime in thirteen years, we delivered our largesl-ever digital symptom awareness campaign, we supported a record number of patients and families, we rebuilt relationships with volunteers and our wider community and we delivered major system changes through our lobbying and campaign work. We are righuy very proud of our achievements.. however, we know that there is still a great deal of work remaining to be done if we are ID improve pancreatic cancer survival rates and save lives. This means we will have to redouble our efforts in all areas if we are to finally improve the care for patients and get people diagnosed in time for life-saving surgery. 11 is worth noting that as an organisalion Pancreatic Cancer Action could not operate al the same level wilhoul the hard work and dedication of our volunteers. They fulfil such varied roles from campaigners and fundraisers lo reviewing our patient information booklets and of course, serving on our Trustee Board or as Ambassadors. Imthout our volunteers. hardworking staff team. patients and families we could not do what we do. Looking forward to 2024 we plan to build on that proud record of growth and activity we establish￿ in 2023. Vve shall do this through investing more in research, creating new resources lo support patients, recruiting more volunteers, delivering innovative campaigns and promoting our resources for healthcare professionals. We look forward to fighting for each and every patient and their families. Joe Kirwin Chief Executive Dated.. .Q.fjJQ912Q24...... PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) FOR THE YEAR ENDED 31 DECEMBER 2023 The Trustees present their annual report and financial slalements for the year ended 31 December 2023. The financial slalements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's Memorandum and Articles of Association, the Companies Act 2006, the Charities and Trustee Investment (Scollandl Act 2005. the Charities Accounts Iscotlandl Regulations 2006 las amended) and 'A¢counling and Reporting by Charities.. Stslemenl of Recommended Pra¢ti applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 (effective 1 January 20191" ObJectlv&s and actlvltles Our purpose Pancreatic Cancer Action works lo save lives through promob.ng earfier diagnosis of pancreatic cancer. Vve do this through promoting greater awareness of the symptoms of the disease, the funding and development of mèdical èducational programmes, supporting patients through improved infomation about pancreatic cancer either on our website or in print and by funding research. Our vlslon Our vision is that everyone survives pancreatic cancer. Our ml$$lon Our mission is to improve survival rates of pancreatic cancer by ensuring more people are diagnosed earfy and that everyone has access to effective treatments, support, infomiation and care. Objectives The charity's objectives are.. Awareness increase publi¢ awareness and knowledge of pancreatic can¢er and its symptoms lo achieve early diagnosis Campaign and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer Train and provide pioneering educational resources for our medical and healthcare communities Innovative research we fund it, we support il to improve early diagn0515 and develop effective treatments to Improve pancreatic cancer outcomes Offer the provision of practical and emotional support and information to all affected by pancreatic cancer Now - we are the action charity and action is needed more than ever beforel The Trustees have paid due regard lo guidance issued by the Charity Commission in deciding what activities the charity should undertake. The Trustees, actlvltles The Trustees meet regularly to develop and SUPPDrt strategies to meet the charitable objectives. The Trustees currently have a range of skills and experience that range from medicallscientific, legal, corporate governance, finance and PR. Role of volunteers I PCA Action Ambassadors The Charity re￿iVeS the very welcome assistance of volunteers. who help support a range of projects lo raise awareness of pancreatic Can￿r, provide support, review literature and fundraise in their communities. The charity seeks volunteer assistance via the website, social media and by word of mouth. Publlc benefit statement The Trustees confirm that they have complied with the duty in Section 4 of the Charities Act 2011 to have due regard to the Charity Commission's general guidan￿ on public benefit. PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023 Achievements and perfomianc Using some of our objedives as headings and some other key areas not covered above, we have sel wl below highlights of activity and work in 2023 in our ongoing mission lo improve survival rates of pancreatic cancer by ensuring more people are diagnosed early and that everyone has access lo effective Ireatmenls, suppcrt, information and care. f. Awareness - increase public awarone$$ and know19dge of pancreatic cancor and its $ymptoms to achieve early diagnosis Throughout the year Pancreatic Cancer Action provided individuals, communities and organisalions wf(h resources lo help raise and improve symptom awareness of Britain's dèadliest cancer. Vve did this through providing posters, leaflets, booklets, online resources, and occupational health talks. In our mission lo improve early diagnosis and save lives, symptom awareness is key lo ensuring that people approach their GP for support. As well as providing these resou￿$ to individuals and communities free of charge, Pancreatic Cancer Action also took proactive and innovative steps to raise awareness with different communities and target those hard-to- reach groups. This included attending the Health & Wellbeing at Work Show on 14-15 March 2023 al the NEC Bimiingham. This was an opportunity for us lo promote our occupational health reSoUr￿S to organisalions and companies both large and small. Cancèr is a significant and growing issue In the workplace and il also has 8 significant impact on the economy. Issues like cancer can be very difficu￿ lo discuss In the workpL?￿ so through attending the Health & Wellbeing at Work Show we were able lo educate employers about the need lo properly support their employees who might have suspicions of cancer or are going through cancer treatment and just as importantly we were able to provide them with resources and an offer of occupational health training for their employees. Following on from our success the previous year in reaching out lo communities who do not have English as their first language, we took further steps to update our translated online and print health education resources. This meant we could providè quality accredited health information to those who have Polish. Urdu, Punjabi, Bengali, Arabic or Gujarati as their first language. These updates included highly trained medical professionals with their own first language experience reviewing the medical advice lo ensure il was up lo dale and accurate. Not being content with waiting for people with concerns to seek out support, as part of our ongoiry Action on the Ground project we sought Dut communities with a low health literacy lo provide them with symptom awareness resources. This included partnering with The Women's Integration Netr￿0rk in Glasgow to deliver an education talk and provide copies of a "Quick Guide to Pancreatic Cancer" In both Arabic and Urdu lo the large number of non-native English speakers who are part of the Women's Integration Network. Vve also partnered with the Coalfields Regeneration Trust to specifically largel men In former mining communities where heatth literacy is low. This partnership resulted in the production of symptom-awareness beer mats that were distributed to pubs and working men's clubs in areas of high deprivation. The chance of developing pancreatic cancer unfortunately increases with age and therefore we mLJSt take action to reach out to educate older people on the symptoms of pancreatic cancer. One of the ways we did tkis in 2023 was sharing 10,000 symptom awareness leaflets at Gardeners Worfd Live. The demographics of those who attend this event skew older and are more likely lo need this essential information that could save their lives. We also vi511ed a number of older people'5 groups lo deliver symptom awareness talks and provide leaflets to them. Pancreat1¢ Cancer Awareness Month or PCAM in November is normally our best opportunity to get key health information out there to the public and improve symptom awareness. 2023 was the blggest dlgltal symptom awareness campaign ever delivered by Pancreatic Cancer Action. We reached more people than ever before through our innovative and groundbreaking # missed campaign. Through the hashtag missed campaign, we sought to highlight all those who passed away from pancreatic cancer because their symptoms were missed. These symptoms were either missed by healthcare professionals or by the individuals themselves. Collaborative campaigns with Purple Llghts UK and The World Pancreatlc Cancer Coalition continue to see locations across the worfd light up purple to raise awareness during November and in particular on World Pancreatlc Cancer Day. This is largely a supporter focused campaign and has evolved lo include supporters lighting up their towns in support. as well as buildings and landmarks. PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023 Pancreatic CancerAclion had a presence at Glasgow Central Slalion on World Pancreatic Cancer Day, arranged by one of our amazing supporters and Network Rail. We are grateful lo our volunteers and team members that helped make the day a huge Suc￿$$, with music from The Glasgow Rock Choir and various performers throughoLrt the day helping attract lots of attention. Information was shared ￿rith commuters and visitors to the station, with a collection of generous donations. 2. Campaign and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer. As a small charity. we punch well above our weight when influencing governments and campaigning to win changes that ¥MII improve early diagnosis and save lives. Since launching a new ￿mpaIgning and influencing strategy in 2021 we have seen significant steps forward in all Four Nations lo improve early diagnosis. Early in 2023, we worked with a number of bodies lo submit proposals to the National Cancer Board that would take further innovative steps to improve early diagnosis of pancreatic cancer in England. These proposals included.. Expanding Targeted Lung Health Checks lo cover Pancreatic Cancer- Al risk cohorts will be offered an extra scan of the area covering the kidney and pancreas and il only adds 10 -15 seconds to the procedLJre. Pancreatic Cancer Surveillance Coordinators to meet NG85 NICE guidan￿. 10°A of cases are linked lo genetic risk factors. Coordinators will implement high-risk Surveillan￿ protocol to identify these people and enrol them on annual surveillan New case finding protocol for panc￿811¢ cancer in patients with New Onset Diabetes and weight loss. A new algorithm to identify these patients faster and speed up diagnosis Enable direct referrals into urgent can￿r pathways andlor testing from a cenlralised Servi￿ {such as NHS 1111 Cutting the strain on Primary Care, this is an additional roule to diagnosis for those with a combination of 'vague' and 'non-descripl' symptoms. We were very pleased when the National Cancer Board adopted all of these proposals and al the lime of writing these projects are in the process of being piloted. As an organisation, we have continued to be heavily involved in shaping and delivering some of these projects including the new case-finding protocol for pancreatic cancer patients with new onset diabetes and weight loss. We have worked with NHS England and the University of Surrey to develop this project, identify partners, and create a pilot before any further rollout acruss England. We have met as a group once every four to six weeks so we can manage the progress and ensure there are no delays in getting this up and running. We've continued lo seek lo change the key areas of our healthcare system lo improve support and ¢¥e for pancreatic cancer patients. One way we do this is through SLJbmitting consultation responses to governments and public bodies. In 2023 this included bul was not limited to responses to the National Cancer Strategy for England (now the major conditions strategy) the Scottish Cancer Strategy and Action Plan and the NICE suspected cancer consultation. Our consultation responses resulted in governments adopting new proposals to improve early diagnosis of pancreatic cancer. For example, induded in the Scottish Cancer Action Plan published alongside the final strategy il included 8 commitment lo exploring the ways community pha￿naciSts can support the diagnosis of cancer. This has long been an area of work for Pancreatic CancerAclion and was a key part of our submission lo the strategy consullalion. In order to advan￿ and promote our policy proposals in Scodand that had already been adopted in England, we attended the Scottish Conservative Party conference and the Scottish Labour Party conference in the spring. (There was no spring SNP Conference). Members of the team met with MSPS, MPS and councillors lo explain the priorities of Pancreatic Cancer Action and why we needed to take action lo improve the ￿[vIVal rale of pancreatic cancer. During the conferences, we also asked politicians to help us raise awareness of pancreatic cancer symptoms wthin their communities. PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023 Throughout the year we networked and promoted our policy proposals to politicians and health leadws across the UK. In the run-up to the annual Pancreatlc Cancer Awa￿ne$S Month debate at the Scottlsh ParllamenL we provided briefings lo all MSPS on the key issues patients and their families fa￿ in Scotland and our proposals to improve earfy diagnosis and save lives. We also offered MSPS the opportunity to meet with a member of the team and our supporters. As a charity, we attended the annual Scottish Cancer Conference. The Conferen￿ allows us an opportunity to speak directly wth health leaders and promote our accredited education and training for healthcare professionals as well as sharing our priorities for patients. Coming out of the conference il was clear that there is growing support wthin the wider healthcare community for some of the proposals we're putting forward to improve eady diagnosis and save lives. We continue to work in partnorship with the Scottish Cancer Coalition, the Less Survivable Cancers Taskforce, the North Cancer Alliance Iscotlandl, Cancem INorth East Englandl, Cancer 52, One Cancer Voice and a number of other coalitions of cancer charities. This partnership working slrenglhens our voice and makes sure that patients, voices are put at the heart of decision-making by politicians and governments. We continue to be a key partner in the delivery of The SHPBN Pathway Improvement Project Inow called SCOT-HP81. This is delivered by the Scottish Government, NHS Scotland, and cancer charities and parb)ers such as ourselves. Pancreatic Cancer Action have been leading on the patient and public involvement aspect of the project that is already seeing results and redLJcing the lime from suspiryon lo treatment and care for pancreatic cancer patients. 3. Train and provide pioneering educational resources for our medical and healthcare communities. Pancreatic Cancer Action provides accredited e-learning for GPS, Pharmacists and Pharmacy Teams. Our GP e-leaming, hosted by The Royal College of General Practitioners IRCGPI was updated during the year. Various webinars were hosted with ne￿orkS induding members of RCGP Wales and The Wessex Can￿r Allian￿. We continue to provide GP and Phamiacy packs across the UK and thank our community of volunteers who help disseminate information on our resources in their local communities. 4. Innovative research we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes. As a small Charity with limited funds, we are not able lo invest millions into research, the same as larger organisalions. However. by also being a small Charity we are able lo be more innovative and invest, kickslart, pump prime and support research that has the potential lo save lives that might have been looked ov¥ by other organisalions and much larger funders. In anticipation of relaunching our Early Diagnostic Challenge Award in 2024, Pancreatic Cancer Action rejoined The Association of Medical Research Charities also known as The AMRC. The association provides support and advice lo charitiès such as our own when making research grant awards. Since rejoining the association, staff members have partaken in AMRC hosted training lo prepare us for the relaunch of the eady diagnostic challenge award in 2024. We continued to be an active partner in the research project we previously funded with a University of Surrey research team led by Dr Agnieszka Lemanska. The aims Df the study were lo confimi the link between dabetes and pancreatic cancer and to examine the differences in diabetes management and primary care presentation between patients who go on lo develop pancreatic cancer and those who do not. The project was a retrospective case-conlrol study, Interrogating the RCGP database lo provide a large sample size of cases and controls. Multiple variables can be examined from demographics lo diagnostics, number of presentations at primary care to disease management. The project involves examining the GP records of patients with diabetes who went on to develop pancreatic cancer and those who did not develop the disease. Records will be taken from the RCGP database where approximately 9.5 million patients, data are stored. This allows a large sample of patients to be investigated. We have now supported the next stages of the research as we take its findings and implement the new case-finding protocol mentioned above. Pancreatic Cancer Action have been key in leading the patient and public involvement aspect of this work and making sure patients, voices are al the heart of the decEion-making process. In order to continue lo support this research the team at Pancreatic Cancer Action has supported continuing funding applicatlOll5 from the University of Sutrey lo ensure our seed-funded research ha5 an even bigger impact. PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023 Members of the team attended the Preventlon Research Conference in Edinburgh and were able to speak lo academics, scientists, health leaders and politicians about our research and the impact il has had so far. 11 was also an opportunity lo inform partners about the plans lo relaunch the Eady Diagnostic Challenge Award. 5. Offer the provision of practical and emotional support and information to all affected by pancreatic cancer. One of the key ways we offer support lo patients and their families is through our patient and health Information booklets. Our booklets cover a wide range of topics to ensure that patients and their families are getting the support and advice they need. These booklets are provided free of charge and are regulady ordered by both individuals and organisalions such as hospitals and cancer Cenlres. 2023 saw a 33￿￿ increase in the demand for our patient and health infomiation booklets. This meant we were reaching more people than ever before with our accredited hIgtr￿qua1itY support information. Each one of the booklets is independently assessed and accredited by the Patient Information Forum and reviewed by highly trained medical professionals. The booklets are also complemented by our groundbreaking recipe book, which continues to be in high demand amongst patients and also continues lo be provided free of charge thanks lo the generous support of our donors. We continue lo look al how we can expand our offer and range of support for patients and their faffilies going through an incredibly difficult lime. One way in which we are looking lo ensure comprehensive coverage of support information is throLJgh the creation of new patient and health infomiation booklets. As a result, 2023 saw a new genetics booklet and a new booklet for patients and carers begin production. Creating new world- class accredited health information is a long process dLJe to the need to involve and consult medical professionals peer reviewers, lay reviewers, patients and their families, health leaders and other charitable organisalions. However, this process Is necessary to ensure we can provide the best possible support lo the people who need us most. One of the key and most practical ways we can offer support lo patients is through the funding we provide for a Cllnlcal Nursg Speclallsl based al Glasgow Royal Infirmary. Our supporters, fundraising has enabled this post since 2019 and since then they have supported hundreds of individuals. patients. family members. colleagues and members of the public through their work. 2023 began with a new person being appointed to the rde and as part of the Pancreatic Clinical Nurse Specialist team at Glasgow Royal Infimiary, they help to suppcrt over 230 patients per year. This workload indudes interactions with patients in environments such as oulpalient clinics, endoscopy, waid inpalienl areas and telephone clinics. The Pancreatic Clinical Nurse Specialist team al Glasgow Royal Infirmary has over 2,500 Interactions with psb.enls every year across their work at return clinics, weèkly consultant clinics, and weekly nurse-led clinics. In 2023 we hosted our firsl°Purple Hearts Gathering. in Glasgow, providing a relaxed afternoon for our wonderful community of supporters. volunteers and stsff lo engage and Connect during November's Pancreatic Cancer Awareness Month. Fundraising In 2023, income was generated through a wde range of fundraising activities and donations, including our amazing supporters tsking part in challenge events, hosting fundraising activities in their communities and incredible support from corporates. A significant event in the year was the Just Employment Law Summer Ball raising over £120,000 in June 2023. We are forever grateful for their ongoing support and Charity partnership with Pancreatic CancerAclion. Substantial legacies were bequeathed to our charity in 2023 and we value the kind generosity of ppnple affected by pancreatic cancer. We are continually inspired by the energy, enthusiasm and commitment of our supporters who are determined to change the pancreatic cancer story and save more lives through early diagnosis. From dress down days in schools and workplaces. cake stalls, coffee mornings, bingo nights. charity dances, goll days, to distance challenges running, walking. smrimming and climbing. our supporters continLJally put the fun into fundraising and embracing the coloLJr purple, to help raise awareness and ftjnds for pancreatic Can￿r. THANK YOU- we are so grateful for all you do. PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023 Trusts and grants We are very grateful lo the many funders that give so generously towards our initiatives. activities and projects. In 2023 these included £5,000 of unrestricted grants and £57,260 of restricted grants. Flnanclal revlew The results for the year are summarised in the Statement of Financial Activities on page 15. The Trustees are pleased lo report that the charity's incoming resources for 2023 amounted lo £752,50412022". £488,089), 12021." £754,217), 12020." £1,256,477", an exceptional year which included a on&off transfer of £607.560 due to the merger with Pancreati¢ Cancer Scotland and £58,781 through the Coronavirus Job Retention Schemel12019: £786,5051,12018: £892,8511,12017'. £757,812). The Trustees would like to thank all those volunteers, fundraisers and donors corporate, trusts and foundations, as well as individual donors who have Supported the charity over the past years and upon whom we are dependent. Total spending on charitable activities was £465,441 12022". £450,195), 12021." £513,874}, 12020. £437,838) 12019. £609,931112018'. £669,1871,12017. £669,077). The charity achieved a net loss for the year of -£8,077 {2022.' £-241,7411, 12021.. £-87,7401, 12020.. £510,025) 12019. £-115,305112018. £-24,634112017. £-169,3151. Resgrves poll¢y 11 is the policy of the charity that unreslricled funds which have not been designated for a specffic use should be maintained to cover al least 6 months of operating expenditure. The Trustees consider that reserves al this level will ensure that, In the event of a significant diop in funding, they will be able lo continue the charity's current activities while consideration is given to ways in which additional funds may be raised. At 31st December 2023. the charity held reserves of £592,379 of which £283,789 was reslricled. Free reserves stood at £308.590 which is in line wrth the level of the reserves policy established by the board. Stru￿ure. govemance and management The charity is a company limited by guarantee, incorporated in June 2010, and is therefore governed by its Memorandum and Articles of Association. Its company registration number is 07272699 and ils charity numbers are 1137689 (England and Wales) and SC049777 Iscotlandl. The Trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were". H Matthews N Menezes N Mumford S Krag H Goodfellow L Condron D Georgiou R Legg C Carter E Cowan N Longworth L Nylander G Codacci Pisanelli D Slater G Lesca (Resigned 17 March 20241 (Resigned 18 March 20241 (Resigned 23 May 20231 (Resigned 12 June 20241 (Resigned 15 July 20241 (Resigned 2 July 20231 (Appointed 18 March 20241 (Appointed 18 March 20241 (Appointed 18 March 20241 PANCREATIC CANCER ACTION TRUSTEES. REPORT (INCLUDING DIRECTORS. REPORT) (CONTINUED FOR THE YEAR ENDED 31 DECEMBER 2023 None of the Trustees has any beneficial interest in the charity. The members of the company guarantee lo contribute £10 in the event of liquidation. The Trustees continue to keep the Charity's activities under review, pa￿cularlY ￿rith regard to ￿Y major physical or financial risks that may arise from time to time, and to monitor the effectiveness of the system of intemal controls and other variable means, including insurance cover where appropriate, by which those risks already identified by the Trustees can be mitigated. Ststement of Trustees. responsibilities The Trustees, who are also the directors of Pancreatic Cancer Action for the purpose of company law, are responsible for preparing the Trustees, Report and the financial stslemenls in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Praclicel. Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the stale of affairs of the charity and of the incoming resources and application of resources, including the Income and expenditure, of the charitable company for that year. In preparing these financi81 stslemenls, the Trustees are required lo.. select suitable accounting policies and then apply them consistently., observe the methods and principles in the Charities SORP., make judgements and eslimales that are reasonable and prudent., slate whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial slalements., and prepare the financial slalements on the going concern basis unless il is inappropriate lo presume that the charity will continue in operation. The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any lime the financial position of the charity and enable them lo ensure that the financial slalements comply with the Companies Act 2006, the Charities and Trustee Investment (Scollandl Act 2005 and the Charities Accounts Iscollandl Regulations 2006 las amended). They are also responsible for safeguarding the assets of the charity and hence for taking ieasonable steps for the prevention and detection of fraud and other itregularilies. Auditor In a¢cordan¢e with the company's articles, a resolution proposing that Alliotts LLP be reappointed as auditor of the company will be put al a General Meeting. The Trustees. report was approved by the Board of Trustees. G Codaccl Pl$ano111 Chair of Trustees Dated.. 231.0912024 PANCREATIC CANCER ACTION INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF PANCREATIC CANCERACTION Oplnlon We have audited the financial statements of Pancreab'c Cancer Action (the 'charity'l for the year ended 31 December 2023 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial slatemenls, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporb"ng Standard 102 The Financial Reporting Standard applicable the UK and RepublK of Ireland Iuniled Kingdom Generally Accepted Accounting Praclicel. In our opinion, the financial slatemenls.. give a true and fair view of the slate of the charitable company's affairs as at 31 December 2023 and of its incoming resou￿$ and application of resou￿$. for the year then ended.. have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practi￿,. and have been prepared in accordance ¥Mth the requirements of the Companies Act 2006. the Charities and Trustee Investment (Scollandl A¢t 2005 and regulation 8 of the Charrties Accounts (Scollandl Regulations 2006 las amended). Basls for oplnlon We conducted our audit in accordance with International Standards on Auditing IUKI IISAS IUKII and applicable law. Our responsibilities under those standards are further described In the Audilorts ￿Sponsibl1111eS for the audit ol the financial slalements section of our report. We are Independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC'S Ethical Stsndard. and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtsined is sufficient and appropriate lo provide a basis for our opinion. Conclusions relating to going concern In auditing the financial statements, we have conduded that the Trustees, use of the going cOn￿M basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating lo events or conditions that, Individually or collectively, may cast significant doubl on the charity's ability lo continue as a going concern for a period of at least twelve months from when the financial slalements a￿ authorised for issue. Our responsibilities and the responsibilities of the Trustees ￿rith respect to going concern are described in the relevant sections of this report. Other Infomiatlon The other information cornprises the information induded in the annual report other than the finamial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial stslemenls does not cover the other Information and we do not express any form of assurance conclusion Ihereon. Our respon5ibilily is lo read the other Inforrnation and, in doing so, consider whether the other information is materially inconsistent wlh the financial slalements or our knowledge obtained in the course of the audit. or otheMise appears to be materially misstated. If we identify such malerk81 inconsistencies or apparent material misstslemenls, we are required lo determine whether this gives rise to a material misstslemenl in the financial ststements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this Dther information, we are required to report that fact. We have nothing to report in this regard. PANCREATIC CANCER ACTION INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF PANCREATIC CANCERACTION Matters on whlch we are requlred to report by exceptlon We have nothing to report in respect of the followng matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts {Scotlandl Regulations 2006 las amended) require us to report lo you if, in our opinion.. the information given in the financial slalemenls is inconsislenl in any material respect wth the Trustees, report., or sufficient and proper accounting records have not been kept., or the financial slalements are not in agreement with the accounting records", or we have not received all the information and explanations we require for our audit. Responslbllltles of Trustees As explained more fully in the statement of Trustees, responsibilities, the Trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial slalements and for being satisfied that they give a true and fair view, and for such Internal control as the Trustees determine is necessary lo enable the preparation of financial statements that are free from material mi5Statemenl, whether due lo fiaud or error. In preparing the financial slalemenls, the Trustees are responsible for assessing the charity'5 ability to continue as a going concern, disclosing, as applicable, matters related lo going concem and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitsble company or lo cease operations. or have no realistic altemalive but to do so. Audltor's responslbllltles for the audlt of the flnanclal ststements We have been appointed as auditor under section 144 of the Charities Act 2011 and section 4411 Ilcl of the Charities and Trustee Investment IScoUandl Act 2005 and report in accordan￿ with the Acts and relevant regulations made or having effect Ihereunder. Our objectives are lo obtain reasonable assurance about whether the financial slalements as a Wha￿ are free from material misslatemenl, whether due to fraud or error, and lo issue an audilorfs report that includes our opinion. Reasonable assurance is a high level of assurance bul is not a guarantee that an audit conducted in accordance with ISAS IUKI will always delect a material misslalement when it exists. Misslatemenls can arise from fraud or error and are considered material rf. individually or in the aggregate, they could reasonably be expected lo influence the economic decisions of users taken on the basis of these financial slatemenls. Irregularities, induding fraud, are instances of non-compliance wich laws and regulations. We design procedures in line with our responsibilities, outlined above. to detect material misslalements in respect of irregularities, including fraud. The extent lo which our procedures are capable of delecling irregularities. including fraud. is detailed below. Extent to whlch the audlt was consldered capable of detectlng Irregularltles, Includlng fraud Our approa¢h lo identifying and assessing the risks of material misstslemenl in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows.. the engagement partner ensured that the engagement team collectively had the appropriate competen￿, capabilities and skills to identify or recognise non-compliance ￿rith applicable laws and regulations., we identified the laws and regulations applicable lo the company through discussions with Trustees and other management, and from our kno￿edge and experience of the sector., we focused on specrfic laws and regulations which we considered may have 8 direct material effect on the financial slalemenls or the operations of the charitsble company, including the Companies Act 2006, the Charities Act 2011, the Charities SORP, laxalion legislation, data protection, anti-bribery, employment, environmental and health and safely legislation.. we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal Corresponden￿.. and • identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit. 10- PANCREATIC CANCER ACTION INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF PANCREATIC CANCERACTION We assessed the susceplibilily of the charitable company's financial slalemenls to material misslatemenl, including obtaining an understanding of how fraud might occur, by.. making enquiries of management as lo where they considered there was susceplibilily to fraud, their knowledge of actual. suspected and alleged fraud., and considering the intemal controls in place to mitigate risks of fraud and non-compliance with laws and regulations. Audit response to risks identified To address the risk of fraud through management bias and override of controls, we.. perfomied analytical procedures to identify any unusual or unexpected relationships., reviewed all transactions Iisled., assessed whethèr judgements and assumptions made in determining the accounting estimates were indicative of potential bias", and investigated the rationale behind signrficant or unusual transactions. In response to the risk of irregularities and non-¢omplian¢e with laws and regulations. we designed procedures which included. but were not limited to.. • agreeing financial statement disclosures to underfying supporting documentation,. and enquiring of management as to actual and potential liligalion and daims. There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of norFcompliance. Auditing standards also limit the audit procedures required lo identify non